[1] Malaguarnera G,Giordano M,Malaguarnera M,et al. Gut microbiota in alcoholic liver disease:pathogenetic role and therapeutic perspectives.World J Gastroenterol,2014,20(44):16639-48. [2] Liang R,Liu A,Ahmed A,et al. Advances in alcoholic liver disease:An update on alcoholic hepatitis. World J Gastroenterol,2015,21(42):11893-11903. [3] Zhong W,McClain CJ,Zhou Z,et al. The role of zink deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol,2010,298(5):G625-33. [4] Smathers RL,Galligan JJ,Shearn CT,et al. Susceptibility of L- FABP-/- mice to oxidative stress in early-stage alcoholic liver. J Lipid Res,2013,54:1335-1345. [5] Ahmed U,Latham PS,Oates PS. Interactions between hepatic iron and lipid metabolism with possible relevance to steatohepatitis. World J Gastroenterol,2012,18:4651-4658. [6] Kirpich IA,Petrosino J,McClain CJ. et al. Saturated and unsaturated dietary fats differentially modulate ethanol-induced changes in gut microbiome and metabolome in a mouse model of alcoholic liver disease. Am J Pathol,2016,186(4):765-76. [7] Keshavarzian A,Farhadi A,Forsyth CB,et al. Evidence that chronic alcohol exposure promotes intestinal oxidative stress,intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol,2009,50(3):538-547. [8] Orman ES,Odena G,Bataller R. Alcoholic liver disease: pathogenesis,management,and novel targets for therapy. J Gastroenterol Hepatol,2013,28 (Suppl 1):77-84. [9] Mir H,Meena AS,Rao R,et al.Occludin deficiency promotes ethanol-induced disruption of colonic epithelial junctions,gut barrier dysfunction and liver damage in mice. Biochim Biophys Acta,2016,1860(4):765-774. [10] Li X,Chen W,Xu YQ,et al. Toll-like receptor 4 increases intestinal permeability through up-regulation of membrane PKC activity in alcoholic steatohepatitis. Alcohol,2013,47(6):459-465. [11] 李鑫,王晨,徐有青,等. Toll样受体4参与了酒精性肝病肠道高通透性.中华肝脏病杂志,2014,22(2):61-64. [12] Imenshahidi M,Hosseinzadeh H. Berberis vulgaris and berberine:An update review. Phytother Res,2016,30(11):1745-1764. [13] 宋淑莉,曹海龙,王邦茂. 小檗碱治疗消化系统疾病的作用机制研究进展. 国际消化病杂志,2013,33(1):47-49. [14] Habtemariam S. Berberine and inflammatory bowel disease:A concise review. Pharmacol Res,2016,113(Pt A):592-599. [15] Zhu X,Bian H,Gao X. The potential mechanisms of Berberine in the treatment of nonalcoholic fatty liver disease. Molecules,2016,14:21(10):312-316. [16] Ortiz LM,Lombardi P,Scovassi AI,et al.Berberine,an epiphany against cancer. Molecules,2014,19(8):12349-12367. [17] Yan F,Wang LH,Polk DB,et al. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol,2012,302(5): G504-G514. [18] Wang XP,Lei F,Du LJ,et al. Protection of gastrointestinal mucosa from acute heavy alcohol consumption:The effect of Berberine and its correlation with TLR2,4/IL1β-TNFα signaling. PLoS One,2015,10(7):e0134044. [19] Chu M,Ding R,Wang YD,et al. Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor.BMC Complement Altern Med,2014,14:89. [20] Liu CS,Zheng YR,Long XY,et al. Research progress on berberine with a special focus on its oral bioavailability.Fitoterapia,2016,109:274-282. |